-
International Journal of Nanomedicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
(623) Views (287) Full article downloads
Authors: Theresa Barnes, Robert Moots
Published Date May 2007
Volume 2007:2(1) Pages 3 - 7
DOI: http://dx.doi.org/10.2147/IJN.S0
Theresa Barnes, Robert Moots
Academic Rheumatology, University of Liverpool, UK
Abstract: Anti-TNFa therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other infl ammatory diseases. These drugs are powerful and expensive. A new anti-TNFa agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFa with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
Keywords: certolizumab pegol, TNFa, rheumatoid arthritis, nanomolecule
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Interested in being a peer-reviewer?
Click here to register.
- Display new articles on your site
Use our widget to show articles on your own site
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Gold nanoparticles: From nanomedicine to nanosensing
- Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
